Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02729298 | First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors | completed | Phase 1 | 177 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02578797 | A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study | completed | Phase 1 | 45 | Aragon Pharmaceuticals, Inc.INDUSTRY | 5 | Nov 9, 2023 | clinicaltrials |
| NCT03304210 | PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer(PIPAC-nabpac) | completed | Phase 1 | 20 | University Hospital, GhentOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03840200 | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | completed | Phase 1 | 51 | Hoffmann-La RocheINDUSTRY | 5 | Oct 30, 2023 | clinicaltrials |
| NCT05986266 | Evaluating Efficacy of Intravenous Carbetocin Versus Intramyometrial Injection of Adrenaline in Reducing Blood Loss | completed | Phase 1 | 62 | EgymedicalpediaINDUSTRY | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03751436 | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT02897375 | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | completed | Phase 1 | 71 | Emory UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00066729 | Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 9 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00072410 | Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer | completed | Phase 1 | 7 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00292045 | Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer | completed | Phase 1 | 15 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 4, 2023 | clinicaltrials |
| NCT00803569 | Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | completed | Phase 1 | 13 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT05516329 | Study of 18F-Thretide PET/CT in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 49 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00562640 | Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | completed | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT01376505 | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | completed | Phase 1 | 65 | Robert WesolowskiOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT03452332 | Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers | completed | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01705158 | Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum(MYCA) | completed | Phase 1 / Phase 2 | 87 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT00788164 | Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia | completed | Phase 1 | 75 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT04614363 | 68 Ga-PSMA for High Risk Prostate Cancer | completed | Phase 1 / Phase 2 | 80 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion(MpeTK01) | completed | Phase 1 | 19 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT03695380 | A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer | completed | Phase 1 | 77 | Hoffmann-La RocheINDUSTRY | 3 | Aug 14, 2023 | clinicaltrials |
| NCT04718740 | A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer | completed | Phase 1 | 33 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT02232152 | CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 19 | Wake Forest University Health SciencesOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00054106 | Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer | completed | Phase 1 | 25 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00471432 | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | completed | Phase 1 | 40 | NCIC Clinical Trials GroupNETWORK | 0 | Aug 4, 2023 | clinicaltrials |
| NCT02459301 | A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies | completed | Phase 1 | 59 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02499835 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 66 | University of Wisconsin, MadisonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03658447 | PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)(PRINCE) | completed | Phase 1 / Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05963334 | Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer | completed | Phase 1 / Phase 2 | 49 | Cairo UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04456140 | Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study | completed | Phase 1 | 230 | Mayo ClinicOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT03569280 | Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients | completed | Phase 1 | 16 | Kangpu Biopharmaceuticals, Ltd.INDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05549778 | Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC(PEACe) | completed | Phase 1 / Phase 2 | 12 | Jiangnan UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02482311 | Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours | completed | Phase 1 | 92 | AstraZenecaINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT02610075 | Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | completed | Phase 1 | 62 | AstraZenecaINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04179396 | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)(RAMP) | completed | Phase 1 | 8 | pharmaand GmbHINDUSTRY | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01686256 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer | completed | Phase 1 | 12 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01689636 | Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients | completed | Phase 1 | 8 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | completed | Phase 1 / Phase 2 | 136 | pharmaand GmbHINDUSTRY | 5 | Jun 9, 2023 | clinicaltrials |
| NCT04177693 | Pharmacokinetics and Hepatic Safety of EGCG | completed | Phase 1 | 39 | Yale UniversityOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT02106507 | ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate | completed | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT00987753 | Study Evaluating the Safety and Tolerability of L-377202 | completed | Phase 1 / Phase 2 | 13 | University of Alabama at BirminghamOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05140512 | Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® | completed | Phase 1 | 23 | Luye Pharma Group Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT01278914 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Oslo University HospitalOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT03310541 | AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | completed | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 14, 2023source: clinicaltrials